Abstract Body

Background

Shock and kill HIV-1 cure strategies seek to induce proviral gene expression to permit immunological elimination of persistently infected cells under antiretroviral therapy (ART). As HIV-1 Tat potently amplifies proviral transcription, we developed CD4-targeting lipid nanoparticles (LNPs) encapsulating tat mRNA (CD4-LNP-Tat) to drive HIV-1 proviral gene expression in humanized mice (hu-mice). To enable real-time visualization of proviral transcription dynamics and infected cell localization in vivo, we used a replication-complement transmitted/founder HIV-1 reporter virus expressing nanoLuciferase (HIV-1CH040-nLuc), enabling temporal non-invasive bioluminescent imaging (BLI). 

Methods

CD4-targeted LNPs were generated by surface conjugation of the non-depleting anti-CD4 antibody ibalizumab. Hu-mice received intravenous CD4-LNPs encapsulating mRuby or firefly luciferase (FLuc) mRNA to assess cell-specific delivery. For latency reversal studies, mice infected with HIV-1CH040-nLuc and suppressed by ART were intravenously treated with CD4-LNP-Tat. Proviral transcription was monitored longitudinally by BLI and plasma viral loads, p24 protein and cell-associated viral RNA in peripheral blood cells (PBMCs) and tissues were monitored at 7–24 h post-treatment. 

Results

CD4-LNP selectively delivered mRuby mRNA to human CD4⁺ T cells, with minimal off-target uptake. CD4-LNP delivery of firefly luciferase mRNA resulted in transient reporter expression, peaking between 9-24 h post-administration. CD4-LNP-Tat treatment induced a transient increase in HIV-1 expression driven nLuc signal, peaking at 9 h, accompanied by transient on-ART viremia (923–50,610 copies/mL plasma). CD4 expression in PBMCs was reduced by 21.2%–56.8% at 24 h post-treatment, consistent with CD4-targeted delivery. HIV p24 was detected in hCD45⁺hCD3⁺hCD8⁻ cell populations (9.82%–18.3% vs. 0%–2.55% in controls) and the cell-associated viral RNA:DNA ratio in PBMCs and tissues trended upward following treatment.

Conclusions

These findings showcase CD4-targeting LNP-mediated Tat mRNA delivery as a focused approach to induce HIV-1 proviral transcription in vivo during ART. Our approach enables targeted interrogation of latency under ART and the development of controlled latency-reversal strategies for eliminating resilient HIV-1 reservoir to advance cure strategies.